Racial Disparities Revealed in Surgical Outcomes in Gastrointestinal Tract Cancer
May 9th 2022Sajid A. Khan MD, FACS, FSSO, discusses findings from the study on racial disparities in surgical outcomes and quality of care for GI tract cancer, plus what issues need to be addressed to close the gap in care.
Read More
PARP Inhibitors Are Under Study as Treatment Options Beyond BRCA-Mutated Breast Cancer
May 9th 2022Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.
Read More
ARO-HIF2 Lowers HIF2α Expression and Demonstrates Favorable Safety Profile in Clear Cell RCC
May 4th 2022The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.
Read More
Ceralasertib Plus Acalabrutinib Shows Early Activity in High-Risk Relapsed/Refractory CLL
April 30th 2022The combination of ceralasertib and acalabrutinib showed preliminary clinical activity with acceptable tolerability in patients with high-risk, relapsed/refractory chronic lymphocytic leukemia.
Read More
Nemvaleukin Alone and in Combination with Pembrolizumab Produces Efficacy in Advanced RCC
April 26th 2022The IL-2 variant immunotherapy nemvaleukin alfa elicited responses and demonstrated safety as a single agent and in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Read More
Uptake of New Therapies Pushes Treatment Paradigm Forward in Breast Cancer
April 22nd 2022Recent developments across the breast cancer paradigm include the utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer, plus neoadjuvant treatment strategies in triple-negative breast cancer.
Read More
Personalized Medicine Evolves With CDK4/6 Inhibitors, Immunotherapy, and ADCs in Breast Cancer
April 21st 2022Hadeel Assad, MD, discussed how CDK4/6 inhibitors have been implemented into practice and provided updates on key clinical trials in HER2-positive breast cancer and triple-negative breast cancer.
Read More
Research Efforts Seek to Further Explore the Potential of Uproleselan in AML
April 14th 2022Tapan M. Kadia, MD, discusses what makes uproleselan unique from other agents under investigation in acute myeloid leukemia and sheds light on the many research efforts dedicated to further exploring its use in this disease.
Read More
Pembrolizumab Maintains Survival Benefits in 4-year Follow-Up of KEYNOTE-042 in NSCLC in China
April 8th 2022First-line pembrolizumab monotherapy continued to elicit an overall survival benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer without sensitizing EGFR or ALK mutations.
Read More
Hurvitz Highlights Practice-Changing DESTINY-Breast03 Data in HER2+ Metastatic Breast Cancer
April 8th 2022Sara A. Hurvitz, MD, medical oncologist and medical director at the Jonsson Comprehensive Cancer Center Clinical Research Unit, discussed pivotal findings in the HER2-positive treatment landscape that possess the potential to change practice.
Read More
Study Reveals Increased Disparities in Cervical Cancer Screening Linked With COVID-19 Pandemic
April 7th 2022Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.
Read More
BTK- and Venetoclax-Based Approaches Move the Needle Forward in CLL Management
April 5th 2022Inhye Ahn, MD, discusses the evolving treatment landscape of chronic lymphocytic leukemia, the advances made with BTK inhibitors and venetoclax-based regimens, novel combination regimens under exploration, and other research efforts that are underway.
Read More
Adding Uproleselan to Chemo Could Reduce Chemotherapy-Induced Mucositis in Relapsed/Refractory AML
March 30th 2022Daniel J. DeAngelo, MD, PhD, discusses how the addition of uproleselan to various chemotherapy backbones is being investigated in ongoing clinical trials, plus the encouraging safety data tied to the lowered mucositis levels.
Read More
Geriatric Assessment May Aid Treatment Decisions for Difficult-to-Treat Multiple Myeloma
March 24th 2022Alessandra Larocca, MD, PhD, discusses the use of patient- and disease-related factors that affect treatment decisions for elderly and frail patients with relapsed/refractory multiple myeloma.
Read More
Relatlimab/Nivolumab Combo Represents ‘Paradigm-Changing’ Advance in Metastatic Melanoma
March 24th 2022Hussein A. Tawbi, MD, PhD, discusses the recent FDA approval of relatlimab/nivolumab in metastatic melanoma, the significance of the regulatory decision, and potential avenues for further exploration of the regimen.
Read More
Updated KEYNOTE-564 Data Continue to Underscore Benefit of Adjuvant Pembrolizumab in RCC
March 22nd 2022Toni K. Choueiri, MD, discusses follow-up data from the pivotal phase 3 KEYNOTE-564 examining adjuvant pembrolizumab in patients with clear cell RCC and additional areas that are ripe for further research.
Read More